RT Journal Article SR Electronic T1 Heart injury signs are associated with higher and earlier mortality in coronavirus disease 2019 (COVID-19) JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.02.26.20028589 DO 10.1101/2020.02.26.20028589 A1 Chaomin Wu A1 Xianglin Hu A1 Jianxin Song A1 Chunling Du A1 Jie Xu A1 Dong Yang A1 Dechang Chen A1 Ming Zhong A1 Jinjun Jiang A1 Weining Xiong A1 Ke Lang A1 Yuye Zhang A1 Guohua Shi A1 Lei Xu A1 Yuanlin Song A1 Xin Zhou A1 Ming Wei A1 Junhua Zheng A1 The first batch of medical teams from Shanghai to support Hubei, China and study group YR 2020 UL http://medrxiv.org/content/early/2020/02/29/2020.02.26.20028589.abstract AB Importance Heart injury can be easily induced by viral infection such as adenovirus and enterovirus. However, whether coronavirus disease 2019 (COVID-19) causes heart injury and hereby impacts mortality has not yet been fully evaluated.Objective To explore whether heart injury occurs in COVID-19 on admission and hereby aggravates mortality later.Design, Setting, and Participants A single-center retrospective cohort study including 188 COVID-19 patients admitted from December 25, 2019 to January 27, 2020 in Wuhan Jinyintan Hospital, China; follow up was completed on February 11, 2020.Exposures High levels of heart injury indicators on admission (hs-TNI; CK; CK-MB; LDH; α-HBDH).Main Outcomes and Measures Mortality in hospital and days from admission to mortality (survival days).Results Of 188 patients with COVID-19, the mean age was 51.9 years (standard deviation: 14.26; range: 21∼83 years) and 119 (63.3%) were male. Increased hs-TnI levels on admission tended to occur in older patients and patients with comorbidity (especially hypertension). High hs-TnI on admission (≥ 6.126 pg/mL), even within the clinical normal range (0∼28 pg/mL), already can be associated with higher mortality. High hs-TnI was associated with increased inflammatory levels (neutrophils, IL-6, CRP, and PCT) and decreased immune levels (lymphocytes, monocytes, and CD4+ and CD8+ T cells). CK was not associated with mortality. Increased CK-MB levels tended to occur in male patients and patients with current smoking. High CK-MB on admission was associated with higher mortality. High CK-MB was associated with increased inflammatory levels and decreased lymphocytes. Increased LDH and α-HBDH levels tended to occur in older patients and patients with hypertension. Both high LDH and α-HBDH on admission were associated with higher mortality. Both high LDH and α-HBDH were associated with increased inflammatory levels and decreased immune levels. hs-TNI level on admission was negatively correlated with survival days (r= -0.42, 95% CI= -0.64∼-0.12, P=0.005). LDH level on admission was negatively correlated with survival days (r= -0.35, 95% CI= -0.59∼-0.05, P=0.022).Conclusions and Relevance Heart injury signs arise in COVID-19, especially in older patients, patients with hypertension and male patients with current smoking. COVID-19 virus might attack heart via inducing inflammatory storm. High levels of heart injury indicators on admission are associated with higher mortality and shorter survival days. COVID-19 patients with signs of heart injury on admission must be early identified and carefully managed by cardiologists, because COVID-19 is never just confined to respiratory injury.Question Does coronavirus disease 2019 (COVID-19) cause heart injury and hereby impact mortality?Findings In this retrospective cohort study including 188 patients with COVID-19, patients with high levels of high-sensitivity cardiac troponin I (hs-TNI) on admission had significantly higher mortality (50.0%) than patients with moderate or low levels of hs-TNI (10.0% or 9.1%). hs-TNI level on admission was significantly negatively correlated with survival days (r= -0.42, 95% CI= -0.64∼-0.12, P=0.005).Meaning COVID-19 patients with signs of heart injury on admission must be early identified and carefully managed by cardiologists, in order to maximally prevent or rescue heart injury-related mortality in COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by The National Natural Science Foundation of China (NSFC) (81972393, 81772705, 31570775), NSFC (81630001, 81770075), Shanghai Municipal Key Clinical Specialty (shslczdzk02201) and Shanghai Top-Priority Clinical Key Disciplines Construction Project (2017ZZ02013), Sub-specialist project of Qingpu Branch of Zhongshan Hospital, Fudan university (YZK 2019-04), 2019 Hospital-level National Natural Science Foundation Incubation Project (QYP 2019-03), Science and technology development fund of Qingpu district science and technology commission in 2018 (QKY 2018-01), Academic Leader of Shanghai Qingpu District Healthcare Commission (WD2019-36), Shanghai key discipline of medicine (ZK2019B07 SZ2019-1), NSFC(81870035), Project of Shanghai municipal commission of health and family planning (201740210).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are available from the corresponding author upon appropriate request.